Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification

Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung...

Full description

Bibliographic Details
Main Author: Kentaro Inamura
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00193/full
id doaj-24033570234b45c68eeeecc734889b4a
record_format Article
spelling doaj-24033570234b45c68eeeecc734889b4a2020-11-25T00:57:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2017-08-01710.3389/fonc.2017.00193270057Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO ClassificationKentaro Inamura0Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, JapanLung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles. This review focuses on recent developments in the molecular profiling of lung cancer and provides perspectives on updated diagnostic concepts in the new 2015 WHO classification. The WHO classification will require additional revisions to allow for reliable, clinically meaningful tumor diagnoses as we gain a better understanding of the molecular characteristics of lung cancer.http://journal.frontiersin.org/article/10.3389/fonc.2017.00193/fulladenocarcinomadriver mutationgenetic alterationhistologymolecular pathologylung cancer
collection DOAJ
language English
format Article
sources DOAJ
author Kentaro Inamura
spellingShingle Kentaro Inamura
Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
Frontiers in Oncology
adenocarcinoma
driver mutation
genetic alteration
histology
molecular pathology
lung cancer
author_facet Kentaro Inamura
author_sort Kentaro Inamura
title Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
title_short Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
title_full Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
title_fullStr Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
title_full_unstemmed Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
title_sort lung cancer: understanding its molecular pathology and the 2015 who classification
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2017-08-01
description Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles. This review focuses on recent developments in the molecular profiling of lung cancer and provides perspectives on updated diagnostic concepts in the new 2015 WHO classification. The WHO classification will require additional revisions to allow for reliable, clinically meaningful tumor diagnoses as we gain a better understanding of the molecular characteristics of lung cancer.
topic adenocarcinoma
driver mutation
genetic alteration
histology
molecular pathology
lung cancer
url http://journal.frontiersin.org/article/10.3389/fonc.2017.00193/full
work_keys_str_mv AT kentaroinamura lungcancerunderstandingitsmolecularpathologyandthe2015whoclassification
_version_ 1725223082180739072